Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Systems Licenses Eukarion Compounds to Minerva, Names New CEO

NEW YORK (GenomeWeb News) — Proteome Systems has licensed its Eukarion portfolio of small-molecule drug compounds to Minerva Healthcare, which is developing treatments for dermatological and other diseases, Proteome Systems said last week. 
The company also said it has appointed Jenny Harry CEO, replacing Stephen Porges. Harry has been deputy CEO since 2005.
Under the terms of the Minerva agreement, Proteome Systems will receive $4 million upfront and will gain a 10 percent stake in Minerva, as well as a milestone payment for clinical development and 12 percent of royalties from product sales.
Minerva is a new venture founded by Athena Diagnostics, Ivax Pharmaceuticals, and Impax Pharmaceuticals, Proteome Systems said.
Proteome Systems said the license is subject to Minerva’s ability to raise its initial capital.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.